Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL2095208

COBICISTAT
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1

Basic Information

ChEMBL ID CHEMBL2095208
Name COBICISTAT
Phase Approved
Structure Type MOL
InChI Key ZCIGNRJZKPOIKD-CQXVEOKZSA-N
Therapeutic ✓ Yes

Known Names

Cobicistat Cobicistat component of evotaz Cobicistat component of genvoya Cobicistat component of prezcobix Cobicistat component of rezolsta Cobicistat component of stribild Cobicistat component of symtuza Cobicistat on silicon dioxide Cobicistat, (r,r,s)- GS-9350 Tybost
5
Targets
6
Activities
3
Assay Types
0
PK Parameters
12
Publications
11
Known Names
16
Indications
1
Mechanisms

Molecular Properties

776.0
MW (Da)
6.00
ALogP
10
HBA
3
HBD
138.0
PSA (Ų)
0.11
QED
2
Ro5 Violations
19
Rot. Bonds

Drug Information

Molecule Type Small molecule
First Approval 2012
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Oral

Flags

Natural Product
USAN Stem -stat
USAN Year 2009

Extended Properties

Molecular Formula C40H53N7O5S2
MW 776.04
Aromatic Rings 4
Heavy Atoms 54
NP-Likeness -1.14

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Cytochrome P450 3A inhibitor INHIBITOR Cytochrome P450 3A

Indications

HIV Infections HIV Infections Infections Acquired Immunodeficiency Syndrome Pneumonia, Pneumocystis Severe Acute Respiratory Syndrome Leukemia, Myeloid, Acute Neoplasms Carcinoma, Pancreatic Ductal Insulin Resistance Leukemia, Biphenotypic, Acute Malaria Pancreatic Neoplasms Pancreatic Neoplasms Precursor Cell Lymphoblastic Leukemia-Lymphoma Carcinoma, Non-Small-Cell Lung

ATC Classification

V03AX03
cobicistat
Level 1: VARIOUS
Level 2: ALL OTHER THERAPEUTIC PRODUCTS

Activity Summary

IC50 4 meas. best 6.82
EC50 1 meas. best 5.56
Kd 1 meas. best 5.66

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
Cytochrome P450 3A4
CHEMBL340
IC50 6.82 6.82 150.0 1
Replicase polyprotein 1ab
CHEMBL4523582
Kd 5.66 5.66 2200.0 1
SARS-CoV-2
CHEMBL4303835
EC50 5.56 5.56 2740.0 1
Replicase polyprotein 1ab
CHEMBL4523582
IC50 5.17 5.17 6700.0 1
Cytochrome P450 2D6
CHEMBL289
IC50 5.04 5.04 9200.0 1
Broad substrate specificity ATP-binding cassette transporter ABCG2
CHEMBL5393
IC50 4.23 4.23 59000.0 1

Activity Data Samples

Top measurements by pChEMBL value

Literature References

PubMed DOI Target Context # Activities
- 10.1101/2020.04.21.054387 SARS-CoV-2 2
37659195 10.1016/j.ejmech.2023.115772 Replicase polyprotein 1ab 2
24412072 10.1016/j.bmcl.2013.12.057 Protease 1
24412072 10.1016/j.bmcl.2013.12.057 Cytochrome P450 3A4 1
24412072 10.1016/j.bmcl.2013.12.057 Human immunodeficiency virus 1 1
24412072 10.1016/j.bmcl.2013.12.057 Cytochrome P450 2C19 1
24412072 10.1016/j.bmcl.2013.12.057 Cytochrome P450 1A2 1
24412072 10.1016/j.bmcl.2013.12.057 Cytochrome P450 2D6 1
24412072 10.1016/j.bmcl.2013.12.057 Cytochrome P450 2C9 1
24412072 10.1016/j.bmcl.2013.12.057 Nuclear receptor subfamily 1 group I member 2 1
35483322 10.1016/j.ejmech.2022.114346 Broad substrate specificity ATP-binding cassette transporter ABCG2 1
37659195 10.1016/j.ejmech.2023.115772 SARS-CoV-2 1

Data from ChEMBL 36 via Core Engine